WHWK Whitehawk Therapeutics, Inc.
Financings ·
Whitehawk agreed to sell 4,330,866 shares at $3.92 and 17,991,021 pre-funded warrants in a PIPE financing. The company expects gross proceeds of about $87.5 million and a May 14, 2026 closing.
KAKEN INVESTMENTS INC. paid $102.4 million in cash at closing on March 25, 2025, after purchase price adjustments, for 100% of the stock of Aadi Subsidiary, Inc.
The buyer paid the cash on closing after purchase price adjustments. The deal was signed on December 19, 2024 under the company's former name, Aadi Bioscience.
Aadi Bioscience closed a private placement of about $100 million on March 4, 2025, selling 21,592,000 shares at $2.40 and pre-funded warrants for 20,076,500 more shares. The company says the money, with the FYARRO sale, should fund operations into 2028.
Aadi Bioscience's preliminary proxy, filed January 21, 2025, asks holders to approve a $100 million cash sale of its FYARRO business to Kaken and a private placement of 21,592,000 shares at $2.40 each. The meeting date is still blank in that filing.
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $7.1 million | $26.0 million |
| Research and development | $91.0 million | $51.0 million |
| Net income (loss) | -$20.6 million | -$63.7 million |
| Cash from operations | -$97.4 million | -$59.5 million |
| Cash and equivalents | $37.6 million | $28.7 million |
| Short-term investments | $108.1 million | $18.6 million |
Our latest story on this, dated May 13, 2026: "Whitehawk Therapeutics agrees to $87.5 million private placement of stock and warrants". The story links the filing or release it is based on. Read the story.
Whitehawk Therapeutics, Inc. trades under the ticker WHWK on NASDAQ.
Whitehawk Therapeutics, Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:3350; LS:A3CSR9.
The SEC Central Index Key (CIK) for Whitehawk Therapeutics, Inc. is 1422142. Its filings are on SEC EDGAR.
57,009,010 shares as of 2026-08-03, per the cover page of its 10-Q filed 2026-08-06.
Our directory records Whitehawk Therapeutics, Inc. under United States.
Our directory classifies Whitehawk Therapeutics, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Whitehawk Therapeutics, Inc. is US00032Q1040.
aibio.space lists Whitehawk Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
$7.1 million for the fiscal year ended Dec 31, 2025, as reported to the SEC.
Whitehawk Therapeutics, Inc. reported a net loss of $20.6 million for the fiscal year ended Dec 31, 2025, and used $97.4 million of cash in operations, per its annual report to the SEC.
$91.0 million in the fiscal year ended Dec 31, 2025, per its annual report.
$190.0 million in cash and short-term investments at Jun 30, 2026, per its 10-Q.
Our latest story on Whitehawk Therapeutics, dated May 13, 2026: "Whitehawk Therapeutics agrees to $87.5 million private placement of stock and warrants". Whitehawk agreed to sell 4,330,866 shares at $3.92 and 17,991,021 pre-funded warrants in a PIPE financing. The company expects gross proceeds of about $87.5 million and a May 14, 2026 closing. Source.
Reported a financing. SEC Form 8-K (Items 1.01,3.02,7.01,9.01). Source
Set up an at-the-market program to sell shares over time. SEC Form 424B5. Source
Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 2.01,9.01). Source
Reported a financing. SEC Form 8-K (Items 1.01,5.07,7.01,9.01). Source
Filed documents for a merger or acquisition. SEC Form PREM14A. Source
Reported a financing. SEC Form 8-K (Items 1.01,3.02,5.02,7.01,9.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio